CN1688692A - 含有抗磷脂酰肌醇蛋白聚糖3抗体的细胞生长抑制剂 - Google Patents
含有抗磷脂酰肌醇蛋白聚糖3抗体的细胞生长抑制剂 Download PDFInfo
- Publication number
- CN1688692A CN1688692A CNA028125703A CN02812570A CN1688692A CN 1688692 A CN1688692 A CN 1688692A CN A028125703 A CNA028125703 A CN A028125703A CN 02812570 A CN02812570 A CN 02812570A CN 1688692 A CN1688692 A CN 1688692A
- Authority
- CN
- China
- Prior art keywords
- antibody
- cell
- glypican
- activity
- cytostatic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims (12)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001189443 | 2001-06-22 | ||
JP189443/2001 | 2001-06-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100960379A Division CN101240022B (zh) | 2001-06-22 | 2002-06-21 | 含有抗磷脂酰肌醇蛋白聚糖3抗体的细胞生长抑制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1688692A true CN1688692A (zh) | 2005-10-26 |
CN1314803C CN1314803C (zh) | 2007-05-09 |
Family
ID=19028362
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100960379A Expired - Lifetime CN101240022B (zh) | 2001-06-22 | 2002-06-21 | 含有抗磷脂酰肌醇蛋白聚糖3抗体的细胞生长抑制剂 |
CNB028125703A Expired - Lifetime CN1314803C (zh) | 2001-06-22 | 2002-06-21 | 含有抗磷脂酰肌醇蛋白聚糖3抗体的细胞生长抑制剂 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100960379A Expired - Lifetime CN101240022B (zh) | 2001-06-22 | 2002-06-21 | 含有抗磷脂酰肌醇蛋白聚糖3抗体的细胞生长抑制剂 |
Country Status (15)
Country | Link |
---|---|
US (3) | US20040236080A1 (zh) |
EP (3) | EP1780273B1 (zh) |
JP (7) | JP4281869B2 (zh) |
KR (3) | KR20080077295A (zh) |
CN (2) | CN101240022B (zh) |
AT (2) | ATE407204T1 (zh) |
AU (2) | AU2002315857B2 (zh) |
CA (1) | CA2451493C (zh) |
CY (1) | CY1113854T1 (zh) |
DE (2) | DE60228721D1 (zh) |
DK (2) | DK2208784T3 (zh) |
ES (3) | ES2353335T3 (zh) |
HK (2) | HK1079547A1 (zh) |
PT (2) | PT1411118E (zh) |
WO (1) | WO2003000883A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102046200A (zh) * | 2008-04-04 | 2011-05-04 | 中外制药株式会社 | 肝癌治疗剂 |
US8497355B2 (en) | 2007-09-28 | 2013-07-30 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody having improved kinetics in plasma |
CN104829704B (zh) * | 2014-12-15 | 2016-08-17 | 河北省科学院生物研究所 | 一种磷脂酰肌醇蛋白聚糖gpc3蛋白片段及其应用和制备的杂交瘤细胞株 |
US9975966B2 (en) | 2014-09-26 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing theraputic agent |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
CA2451493C (en) | 2001-06-22 | 2016-08-23 | Chugai Seiyaku Kabushiki Kaisha | Cell growth inhibitors containing anti-glypican 3 antibody |
WO2004022597A1 (ja) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化n端ペプチドに対する抗体 |
IL164848A0 (en) * | 2002-05-23 | 2005-12-18 | Sunnybrook & Womens College | Diagnosis of repatocellular carcinoma |
JPWO2005023301A1 (ja) * | 2003-09-04 | 2006-11-02 | 中外製薬株式会社 | 胆管癌治療剤および検出薬 |
CN111925445A (zh) | 2004-07-09 | 2020-11-13 | 中外制药株式会社 | 抗-磷脂酰肌醇蛋白聚糖3抗体 |
PT1800693E (pt) | 2004-08-24 | 2013-08-23 | Chugai Pharmaceutical Co Ltd | Terapia adjuvante utilizando anticorpo antiglipicana |
KR101296931B1 (ko) * | 2004-10-26 | 2013-08-14 | 추가이 세이야쿠 가부시키가이샤 | 변형된 당쇄를 갖는 항-글리피칸 3 항체 |
EP3623473A1 (en) * | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
CN101233774A (zh) | 2005-08-03 | 2008-07-30 | 松下电器产业株式会社 | 基站装置、通信终端装置和多载波通信方法 |
US20070087005A1 (en) * | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
US7723043B2 (en) * | 2006-01-04 | 2010-05-25 | Picobella, Lp | Methods for screening for prostate cancer |
JP5624276B2 (ja) | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | 抗体の血中動態を制御する方法 |
US9670269B2 (en) * | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
WO2009012394A1 (en) | 2007-07-17 | 2009-01-22 | Medarex, Inc. | Monoclonal antibodies against glypican-3 |
ES2566957T3 (es) * | 2007-09-26 | 2016-04-18 | Chugai Seiyaku Kabushiki Kaisha | Región constante de anticuerpo modificado |
EP3689912A1 (en) | 2007-09-26 | 2020-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
EP2236604B1 (en) * | 2007-12-05 | 2016-07-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-nr10 antibody and use thereof |
TWI564021B (zh) | 2008-04-11 | 2017-01-01 | Chugai Pharmaceutical Co Ltd | Repeated binding of antigen to antigen binding molecules |
TWI440469B (zh) * | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
TWI682995B (zh) | 2009-03-19 | 2020-01-21 | 日商中外製藥股份有限公司 | 抗體恆定區域改變體 |
JP5837821B2 (ja) | 2009-09-24 | 2015-12-24 | 中外製薬株式会社 | 抗体定常領域改変体 |
JP5889181B2 (ja) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
MX355060B (es) | 2010-11-17 | 2018-04-03 | Chugai Pharmaceutical Co Ltd | Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea. |
MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
CN103429737B (zh) | 2010-11-30 | 2020-07-14 | 中外制药株式会社 | 细胞毒诱导治疗剂 |
US20120190049A1 (en) * | 2010-12-10 | 2012-07-26 | University Of Washington Through Its Center For Commercialization | Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles |
US20140093496A1 (en) | 2011-02-25 | 2014-04-03 | Chugai Seiyaku Kabushiki Kaisha | Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY |
EP3825325A3 (en) | 2011-03-30 | 2021-10-13 | Chugai Seiyaku Kabushiki Kaisha | Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity |
TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
CA2850322C (en) | 2011-09-30 | 2023-10-10 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule inducing immune response to target antigen |
SG11201401101XA (en) | 2011-09-30 | 2014-08-28 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule for promoting loss of antigens |
EP2765192A4 (en) | 2011-10-05 | 2015-04-15 | Chugai Pharmaceutical Co Ltd | ANTIGEN BINDING MOLECULE FOR PROMOTING THE PLASMA CLAIR OF AN ANTIGEN COMPRISING A SACCHARIDIC CHAIN TYPE RECEPTOR BINDING DOMAIN |
TW202015731A (zh) | 2012-02-24 | 2020-05-01 | 日商中外製藥股份有限公司 | 經FcγRIIB促進抗原消失之抗原結合分子 |
CA2874721A1 (en) | 2012-05-30 | 2013-12-05 | Tomoyuki Igawa | Target tissue-specific antigen-binding molecule |
US9409994B2 (en) | 2012-06-01 | 2016-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High-affinity monoclonal antibodies to glypican-3 and use thereof |
EP4119947A1 (en) | 2012-12-21 | 2023-01-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
TWI693073B (zh) | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑 |
DK3050896T3 (da) | 2013-09-27 | 2021-07-19 | Chugai Pharmaceutical Co Ltd | Fremgangsmåde til fremstilling af en polypeptid-heteromultimer |
SG11201604495PA (en) | 2013-12-04 | 2016-07-28 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules |
CN106459959A (zh) | 2014-05-08 | 2017-02-22 | 中外制药株式会社 | 对gpc3靶向治疗剂疗法有效的患者施用的gpc3靶向治疗剂 |
US9926377B2 (en) * | 2014-05-22 | 2018-03-27 | Genentech, Inc. | Anti-GPC3 antibodies and immunoconjugates |
CA2963760A1 (en) | 2014-12-19 | 2016-06-23 | Yoshinao Ruike | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
CN113045650A (zh) | 2014-12-19 | 2021-06-29 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
DK3245219T3 (da) * | 2015-01-16 | 2020-06-29 | Glyp Holdings Pty Ltd | Glypicanepitoper og anvendelser deraf |
EA201791754A1 (ru) | 2015-02-05 | 2019-01-31 | Чугаи Сейяку Кабусики Кайся | АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ |
KR101892883B1 (ko) | 2015-02-27 | 2018-10-05 | 추가이 세이야쿠 가부시키가이샤 | Il-6 관련 질환 치료용 조성물 |
WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
EP3318879B1 (en) | 2015-07-01 | 2020-10-21 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting therapeutic agent which is administered to patient for whom the gpc3-targeting therapeutic agent is effective |
AU2016304060B2 (en) * | 2015-08-03 | 2022-09-29 | Crage Medical Co., Limited | Antibody against glypican-3 and application thereof |
KR101796688B1 (ko) | 2015-10-29 | 2017-12-01 | 재단법인 목암생명과학연구소 | 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물 |
EP3373968B1 (en) | 2015-11-09 | 2024-04-17 | The Children's Hospital of Philadelphia | Glypican 2 as a cancer marker and therapeutic target |
EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
JP7219005B2 (ja) | 2015-12-28 | 2023-02-07 | 中外製薬株式会社 | Fc領域含有ポリペプチドの精製を効率化するための方法 |
TW202214700A (zh) | 2016-03-14 | 2022-04-16 | 日商中外製藥股份有限公司 | 用於癌之治療的細胞傷害誘導治療劑 |
JP6430025B2 (ja) * | 2016-03-15 | 2018-11-28 | 中外製薬株式会社 | Pd−1系結合アンタゴニストおよび抗gpc3抗体を使用して癌を治療する方法 |
CA3026050A1 (en) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
JP7125347B2 (ja) | 2016-08-22 | 2022-08-24 | 中外製薬株式会社 | ヒトgpc3ポリペプチドを発現する遺伝子改変非ヒト動物 |
KR102533814B1 (ko) | 2016-11-28 | 2023-05-19 | 추가이 세이야쿠 가부시키가이샤 | 리간드 결합 활성을 조정 가능한 리간드 결합 분자 |
WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法 |
EP3684413A1 (en) | 2017-09-20 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent |
BR112020010248A2 (pt) | 2017-11-28 | 2020-11-10 | Chugai Seiyaku Kabushiki Kaisha | molécula de ligação do ligante tendo atividade de ligação do ligante ajustável |
AR114112A1 (es) | 2018-02-15 | 2020-07-22 | Seattle Genetics Inc | Anticuerpos de glipicano 3 y conjugados de los mismos |
US20210253672A1 (en) | 2018-05-30 | 2021-08-19 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule containing single domain antibody |
MX2020013977A (es) | 2018-06-22 | 2021-06-15 | Kite Pharma Inc | Proteínas quiméricas transmembrana y usos de las mismas. |
EP3860716A2 (en) | 2018-10-01 | 2021-08-11 | Adicet Bio Inc. | Compositions and methods regarding engineered and non-engineered gamma-delta -t cells for treatment of solid tumors |
WO2020086758A1 (en) | 2018-10-23 | 2020-04-30 | Dragonfly Therapeutics, Inc. | Heterodimeric fc-fused proteins |
US20220153875A1 (en) | 2019-03-19 | 2022-05-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain |
EP4023230A4 (en) | 2019-06-05 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | ANTIBODY CLEAVAGE SITE BINDING MOLECULE |
CN114127277A (zh) | 2019-06-05 | 2022-03-01 | 中外制药株式会社 | 蛋白酶底物和包含蛋白酶切割序列的多肽 |
JP2023522972A (ja) | 2020-04-22 | 2023-06-01 | ドラゴンフライ セラピューティクス, インコーポレイテッド | ヘテロ二量体Fc融合タンパク質のための製剤、投薬量レジメン、及び製造工程 |
KR20230048059A (ko) | 2020-07-31 | 2023-04-10 | 추가이 세이야쿠 가부시키가이샤 | 키메라 수용체를 발현하는 세포를 포함하는 의약 조성물 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04228089A (ja) | 1990-05-15 | 1992-08-18 | Kanegafuchi Chem Ind Co Ltd | 高カルシウム血症治療・予防剤 |
AU7949394A (en) * | 1993-11-19 | 1995-06-06 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human medulloblastomatous cell |
KR20050085971A (ko) | 1995-04-27 | 2005-08-29 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
UA76934C2 (en) * | 1996-10-04 | 2006-10-16 | Chugai Pharmaceutical Co Ltd | Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody |
JP3587664B2 (ja) | 1996-10-04 | 2004-11-10 | 中外製薬株式会社 | 再構成ヒト抗hm1.24抗体 |
JP4228089B2 (ja) | 1997-03-11 | 2009-02-25 | 株式会社ニコン | 過電流検知機構およびそれを用いた電子閃光装置 |
US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
US7052873B2 (en) | 1997-10-03 | 2006-05-30 | Chugai Seiyaku Kabushiki Kaisha | Natural human antibody |
JP3445153B2 (ja) * | 1998-06-04 | 2003-09-08 | 富士通株式会社 | 電話番号一時的使用装置及び方法 |
CA2382587A1 (en) | 1999-08-23 | 2001-03-01 | Chugai Seiyaku Kabushiki Kaisha | Hm1.24 antigen expression potentiators |
CA2451493C (en) | 2001-06-22 | 2016-08-23 | Chugai Seiyaku Kabushiki Kaisha | Cell growth inhibitors containing anti-glypican 3 antibody |
-
2002
- 2002-06-21 CA CA2451493A patent/CA2451493C/en not_active Expired - Lifetime
- 2002-06-21 WO PCT/JP2002/006237 patent/WO2003000883A1/ja active Application Filing
- 2002-06-21 PT PT02741243T patent/PT1411118E/pt unknown
- 2002-06-21 ES ES07002896T patent/ES2353335T3/es not_active Expired - Lifetime
- 2002-06-21 KR KR1020087019090A patent/KR20080077295A/ko not_active Application Discontinuation
- 2002-06-21 KR KR1020097019979A patent/KR100953520B1/ko active IP Right Grant
- 2002-06-21 EP EP07002896A patent/EP1780273B1/en not_active Expired - Lifetime
- 2002-06-21 EP EP02741243A patent/EP1411118B1/en not_active Expired - Lifetime
- 2002-06-21 AT AT02741243T patent/ATE407204T1/de active
- 2002-06-21 ES ES02741243T patent/ES2312586T3/es not_active Expired - Lifetime
- 2002-06-21 AT AT07002896T patent/ATE483801T1/de not_active IP Right Cessation
- 2002-06-21 EP EP10003378A patent/EP2208784B1/en not_active Expired - Lifetime
- 2002-06-21 PT PT100033786T patent/PT2208784E/pt unknown
- 2002-06-21 DK DK10003378.6T patent/DK2208784T3/da active
- 2002-06-21 DE DE60228721T patent/DE60228721D1/de not_active Expired - Lifetime
- 2002-06-21 US US10/481,524 patent/US20040236080A1/en not_active Abandoned
- 2002-06-21 CN CN2007100960379A patent/CN101240022B/zh not_active Expired - Lifetime
- 2002-06-21 CN CNB028125703A patent/CN1314803C/zh not_active Expired - Lifetime
- 2002-06-21 KR KR1020037016776A patent/KR100877176B1/ko active IP Right Grant
- 2002-06-21 DK DK02741243T patent/DK1411118T3/da active
- 2002-06-21 JP JP2003507268A patent/JP4281869B2/ja not_active Expired - Lifetime
- 2002-06-21 DE DE60237929T patent/DE60237929D1/de not_active Expired - Lifetime
- 2002-06-21 AU AU2002315857A patent/AU2002315857B2/en not_active Expired
- 2002-06-21 ES ES10003378T patent/ES2399028T3/es not_active Expired - Lifetime
-
2005
- 2005-04-28 JP JP2005133154A patent/JP2005225892A/ja not_active Withdrawn
- 2005-12-15 HK HK05111542A patent/HK1079547A1/xx not_active IP Right Cessation
-
2006
- 2006-11-06 JP JP2006300276A patent/JP2007051159A/ja not_active Withdrawn
-
2007
- 2007-02-05 US US11/702,780 patent/US7744880B2/en not_active Expired - Lifetime
- 2007-03-22 AU AU2007201255A patent/AU2007201255B2/en not_active Expired
- 2007-06-25 JP JP2007165739A patent/JP2007238632A/ja active Pending
-
2008
- 2008-02-08 JP JP2008028527A patent/JP2008120828A/ja active Pending
- 2008-09-05 JP JP2008228128A patent/JP4347402B2/ja not_active Expired - Lifetime
- 2008-11-07 HK HK08112277.1A patent/HK1120522A1/xx not_active IP Right Cessation
-
2009
- 2009-04-24 JP JP2009105835A patent/JP5596935B2/ja not_active Expired - Lifetime
-
2010
- 2010-04-26 US US12/799,491 patent/US8263077B2/en not_active Expired - Lifetime
-
2013
- 2013-03-29 CY CY20131100264T patent/CY1113854T1/el unknown
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8497355B2 (en) | 2007-09-28 | 2013-07-30 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody having improved kinetics in plasma |
CN102046200A (zh) * | 2008-04-04 | 2011-05-04 | 中外制药株式会社 | 肝癌治疗剂 |
US9975966B2 (en) | 2014-09-26 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing theraputic agent |
US11001643B2 (en) | 2014-09-26 | 2021-05-11 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
CN104829704B (zh) * | 2014-12-15 | 2016-08-17 | 河北省科学院生物研究所 | 一种磷脂酰肌醇蛋白聚糖gpc3蛋白片段及其应用和制备的杂交瘤细胞株 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1314803C (zh) | 含有抗磷脂酰肌醇蛋白聚糖3抗体的细胞生长抑制剂 | |
CN102698267B (zh) | 使用抗磷脂酰肌醇蛋白聚糖‑3抗体的辅助疗法 | |
CN1259973C (zh) | 含有il-6拮抗剂作为有效成分的牛皮癣的预防或治疗剂 | |
CN1893979A (zh) | 血管炎治疗剂 | |
WO2008072723A1 (ja) | 抗Claudin3モノクローナル抗体およびそれを用いる癌の治療および診断 | |
JP2006306895A (ja) | 悪液質治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1079547 Country of ref document: HK |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20060915 Address after: Tokyo, Japan Applicant after: Chugai Pharmaceutical Co.,Ltd. Co-applicant after: Perseus protein Group Co. Address before: Tokyo, Japan Applicant before: Chugai Pharmaceutical Co.,Ltd. Co-applicant before: Hiroyuki Aburatani |
|
ASS | Succession or assignment of patent right |
Owner name: CHOONGWAE PHARMACUTICAL CORP. Free format text: FORMER OWNER: CHOONGWAE PHARMACUTICAL CORP.; APPLICANT Effective date: 20061124 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20061124 Address after: Tokyo, Japan Applicant after: Chugai Pharmaceutical Co.,Ltd. Address before: Tokyo, Japan Applicant before: Chugai Pharmaceutical Co.,Ltd. Co-applicant before: Perseus protein Group Co. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term |
Granted publication date: 20070509 |
|
CX01 | Expiry of patent term |